Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data.
Alexandra RohracherGeorg ZimmermannVicente VillanuevaIñigo GaramendiJosemir W SanderTim WehnerRichard LaugharneElinor Ben-MenachemMartin J BrodieMax C PenselGiancarlo Di GennaroAude MauroussetAdam StrzelczykSylvain RheimsAttila RáczKatja MenzlerVicente Bertol-AlegreIrene García-MoralesFrancisco Javier López-GonzálezManuel ToledoKatherine J CarpenterEugen TrinkaPublished in: Epilepsia (2018)
Across a large, treatment-resistant population, add-on perampanel was retained for ≥1 year by 48% of individuals, and 9% were seizure-free for ≥6 months. TEAEs were in line with previous reports in routine clinical use, and less frequent than in the clinical trial setting. No new or unexpected TEAEs were seen. Despite the limitations of observational studies, our data indicate that some individuals may derive a marked benefit from the use of perampanel.